Loading
3SBio is a Shenyang biologics company whose HER2 antibody inetetamab was approved in China in 2020 for HER2-positive metastatic breast cancer.
3SBio, listed in Hong Kong, is one of China's largest biologics makers, with a long-standing business in recombinant proteins (erythropoietin, thrombopoietin). In oncology its Fc-engineered HER2 antibody inetetamab (Cipterbin) was approved by the NMPA in June 2020 with vinorelbine for HER2-positive metastatic breast cancer. In May 2025 it licensed SSGJ-707, its bispecific antibody against PD-1 and VEGF, to Pfizer for development outside China, where Pfizer calls it PF-08634404; the licence took effect in July 2025 with a USD 1.25 billion upfront payment, up to USD 4.8 billion in milestones and an option for Pfizer to add China.
Inetetamab is 3SBio's HER2 antibody, approved in China in 2020 with vinorelbine for HER2-positive metastatic breast cancer.
SSGJ-612 is an experimental monoclonal antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials, aimed at HER2.
SSGJ-705 is an experimental monoclonal antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials, aimed at PD-1 and HER2.
SSGJ-706 is an experimental bispecific antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials for non-small-cell lung cancer, aimed at PD-1 and PD-L1.
PF-08634404 is an experimental investigational agent whose form is not stated in the registry from Pfizer in phase 3 trials for colorectal cancer, gastric & gastro-oesophageal junction cancer and oesophageal cancer, with its target not yet stated publicly.
Shares Monoclonal antibodies and the tag china.
Shares Monoclonal antibodies and the tag china.
Shares Monoclonal antibodies and the tag china.
Shares Monoclonal antibodies and the tag china.
Shares Monoclonal antibodies and the tag china.
Shares HER2-positive breast cancer and the tag china.
Shares Inetetamab, HER2-positive breast cancer.
Shares PF-08634404, Pfizer (incl. Seagen).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/